

## AuthentiKine <sup>®</sup>

### Human IL-17A Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00203 Size: 96T Sensitivity: 0.4 pg/mL Range: 31.25-2000 pg/mL Usage: For the quantitative detection of human IL-17A concentrations in serum, plasma and cell culture supernatant.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

| Table of content                 | page |
|----------------------------------|------|
| 1. Background                    | 3    |
| 2. Principle                     |      |
| 3. Required Materials            |      |
| 4. Kit Components and Storage    |      |
| 5. Safety Notes                  |      |
| 6. Sample Collection and Storage |      |
| 7. Regent Preparation            |      |
| 8. Assay Procedure Summary       | 6    |
| 9. Validation Data               |      |
| 9.1 Standard curve               |      |
| 9.2 Precision                    |      |
| 9.3 Recovery                     |      |
| 9.4 Sample values                |      |
| 9.5 Sensitivity                  |      |
| 9.6 Linearity                    |      |
| 9.7 Calibration                  |      |
| 9.8 Specificity                  |      |
| 10. References                   | 11   |

#### 1. Background

IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.

#### 2. Principle



# Sandwich ELISA structure (Detection antibody labeled with HRP)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with HRP also binds to the analyte. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

#### 3. Required Materials

3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.

3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.

3.3 Plate washer: automated or manual.

- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.

3.6 Beakers and graduated cylinders.

3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

#### 4. Kit Components and Storage

| Microplate - antibody coated 96-well microplate (8 well × 12 strips)         | 1 plate   | Unopened Kit:                    |
|--|-----------|----------------------------------|
| Protein standard - 2000 pg/bottle; lyophilized                               | 2 bottles |                                  |
| Detection antibody, HRP-conjugated (100×) - 120 µL/vial*                     | 1 vial    | Store at 2-8°C for 6 months or - |
| Additional Diluent AT-00203 - 6 mL/bottle. Only for serum and plasma samples | 1 bottle  | 20°C for 12 months.              |
| Sample Diluent PT 1-ef - 30 mL/bottle. For cell culture supernatant          | 1 bottle  | Opened Kit:                      |
| Sample Diluent PT 3 - 30 mL/bottle. For serum and plasma                     | 1 bottle  | All reagents stored at 2-8°C for |
| Detection Diluent - 30 mL/bottle   | 1 bottle  | 7 days.                          |
| Wash Buffer Concentrate (20×) - 30 mL/bottle                                 | 1 bottle  | Please use a new standard        |
| Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle                          | 1 bottle  | for each assay.                  |
| Stop Solution - 12 mL/bottle   | 1 bottle  | ior cach assay.                  |
| Plate Cover Seals  | 4 pieces  |                                  |

\* Centrifugation immediately before use

#### 5. Safety Notes

5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

5.2 Do not use the kit after the expiration date.

5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.

5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.

5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

#### 6. Sample Collection and Storage

6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at  $\leq$  -20°C. Avoid repeated freeze-thaw cycles.

#### 7. Regent Preparation

**7.1 Wash Buffer (1X):** If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.


**7.2 Detection Antibody, HRP-conjugated (1X):** Dilute 100X Detection Antibody, HRP-conjugated 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Detection Antibody, HRP-conjugated + 990 µL Detection Diluent (Centrifuge the 100 X Detection Antibody solution, HRP-conjugated for a few seconds prior to use)

**7.3 Sample Dilution:** Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 dilution is recommended for cell culture supernatant.

#### 7.4 Standard Serial Dilution:

For serum and plasma samples, add 1 mL Sample Diluent PT 3 in protein standard; For cell culture supernatant, add 1 mL Sample Diluent PT 1-ef in protein standard.



| Add # μL of Standard<br>diluted in the previous<br>step | -       | 500 μL |
|---|---------|--------|--------|--------|--------|--------|--------|
| # μL of Sample Diluent<br>PT 3 or PT 1-ef               | 1000 µL | 500 μL | 500 μL | 500 µL | 500 µL | 500 μL | 500 µL |
|   | "sd7"   | "sd6"  | "sd5"  | "sd4"  | "sd3"  | "sd2"  | "sd1"  |

#### 8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody, HRP-conjugated can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent. 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group;

For serum and plasma samples, add 50 µL of Additional Diluent to all wells (include standard curve), no need incubation and wash;

For cell culture supernatent samples, no need to add Additional Diluent, follow the next step directly.

8.3. Add 100 µL of each standard and sample to the appropriate wells.(Make sure sample addition is uninterrupted and completed within 5 to 10 minutes).

8.4 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C. 8.5 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.
Add 100 µL of 1X Detection antibody, HRP-conjugated solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 40 minutes at 37°C.

8.7 Repeat wash step in 8.5.

8.8 Signal development: Add 100  $\mu$ L of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.

8.9 Quenching color development: Add 100 μL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.10 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.11 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

| Step | Reagent  | Volume | Incubation | Wash           | Notes   |  |
|------|--|--------|------------|----------------|---|--|
| 1    | Additional diluent (Only for serum and plasma sample test)                                       | 50 µL  | 0 min      | Do not<br>wash | Add additional diluent 50 µL per well then add standard and samples immediately |  |
| 2    | Standard and Samples   | 100 µL | 120 min    | 4<br>times     | Cover Wells incubate at 37°C  |  |
| 3    | Diluent Detection antibody, HRP-<br>conjugated Solution  | 100 µL | 40 min     | 4<br>times     | Cover Wells incubate at 37°C  |  |
| 4    | TMB Substrate  | 100 µL | 15-20 min  | Do not<br>wash | Incubate in the dark at 37°C  |  |
| 5    | Stop Solution  | 100 µL | 0 min      | Do not<br>wash | -   |  |
| 6    | Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes. |        |            |                |   |  |


#### 9. Validation Data

#### 9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



| (pg/mL) | 0.D            | Average | Corrected |
|---------|----------------|---------|-----------|
| 0       | 0.041<br>0.036 | 0.039   | -         |
| 31.25   | 0.137<br>0.126 | 0.132   | 0.093     |
| 62.5    | 0.243<br>0.207 | 0.225   | 0.187     |
| 125     | 0.387<br>0.398 | 0.393   | 0.354     |
| 250     | 0.666<br>0.631 | 0.649   | 0.610     |
| 500     | 1.114<br>1.098 | 1.106   | 1.068     |
| 1000    | 1.630<br>1.638 | 1.634   | 1.596     |
| 2000    | 2.283<br>2.308 | 2.296   | 2.275     |



| (pg/mL) | 0.D            | Average | Corrected |
|---------|----------------|---------|-----------|
| 0       | 0.032<br>0.034 | 0.033   | -         |
| 31.25   | 0.135<br>0.145 | 0.140   | 0.107     |
| 62.52   | 0.214<br>0.229 | 0.221   | 0.189     |
| 125     | 0.405<br>0.405 | 0.405   | 0.372     |
| 250     | 0.662<br>0.667 | 0.665   | 0.632     |
| 500     | 1.130<br>1.188 | 1.159   | 1.126     |
| 1000    | 1.722<br>1.786 | 1.754   | 1.721     |
| 2000    | 2.365<br>2.585 | 2.475   | 2.442     |

#### 9.2 Precision

**Intra-assay Precision** (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

**Inter-assay Precision** (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

|        |    | Intra-assay Precision |      |     |        |    | Inter-assay Precision |      |     |
|--------|----|-----------------------|------|-----|--------|----|-----------------------|------|-----|
| Sample | n  | Mean (pg/mL)          | SD   | CV% | Sample | n  | Mean (pg/mL)          | SD   | CV% |
| 1      | 20 | 543.2                 | 13.4 | 2.5 | 1      | 24 | 555.2                 | 31.4 | 5.7 |
| 2      | 20 | 129.4                 | 5.5  | 4.2 | 2      | 24 | 141.8                 | 8.4  | 5.9 |
| 3      | 20 | 30.1                  | 1.9  | 6.4 | 3      | 24 | 28                    | 2.5  | 9.0 |

#### 9.3 Recovery

The recovery of IL-17A spiked to three different levels throughout the range of the assay in various matrices was evaluated.

| Sample Type              |     | Average% of Expected | Range (%) |
|--------------------------|-----|----------------------|-----------|
|                          | 1:2 | 91                   | 74-107    |
| Human plasma             | 1:4 | 89                   | 77-101    |
| Coll culture cupernatant | 1:2 | 99                   | 90-106    |
| Cell culture supernatant | 1:4 | 106                  | 97-116    |

#### 9.4 Sample values

**Serum** - twenty-four serum samples from volunteers were evaluated for human IL-17A in this assay. twenty-two samples measured less than the lowest standard, 31.25 pg/mL. Two samples measured 98.5 pg/mL and 107.5 pg/mL respectively. No medical histories were available for the donors used in this study.

**Cell culture supernatant** - Human peripheral blood mononuclear cells ( $1 \times 10^{6}$  cells/mL) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate. The cells were unstimulated or stimulated with 10 µg/mL PHA. Aliquots of the cell culture supernatant were removed on days 1 and 5 and assayed for levels of human IL-17A.

| Condition    | Day1 (pg/mL) | Day5 (pg/mL) |
|--------------|--------------|--------------|
| Unstimulated | -            | -            |
| Stimulated   | 126.6        | 251.8        |

USA: Proteintech@ptglab.com UK & Europe: Europe@ptglab.com China: Proteintech-CN@ptglab.com 9/11

#### 9.5 Sensitivity

The minimum detectable dose of human IL-17A is 0.4 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

#### 9.6 Linearity

To assess the linearity of the assay, human plasma samples were spiked with high concentrations of human IL-17A and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay. Cell culture supernatant was diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

|      |                      | Human plasma<br>(Sample Diluent PT 3) | Cell culture supernatant<br>(Sample Diluent PT 1-ef) |
|------|----------------------|---------------------------------------|--|
| 1.2  | Average% of Expected | 80                                    | 100  |
| 1:2  | Range (%)            | 73-90                                 | -  |
| 1.1  | Average% of Expected | 88                                    | 109  |
| 1:4  | Range (%)            | 75-102                                | 98-122   |
| 1.0  | Average% of Expected | 85                                    | 103  |
| 1:8  | Range (%)            | 80-92                                 | 86-115   |
| 1:16 | Average% of Expected | 97                                    | 99   |
| 1.10 | Range (%)            | 90-106                                | 94-103   |

#### 9.7 Calibration

The NIBSC/WHO Human IL-17A Reference Reagent 01/420 (rDNA derived), which was intended as a potency standard, was evaluated in this kit. The dose response curve of this Reference Reagent parallels the Proteintech standard curve. To convert sample values obtained with the Authentikine Human IL-17A ELISA kit to approximate NIBSC/WHO 01/420 values, use the equation below.

NIBSC/WHO (01/420) approximate value (IU/mL) = 0.028 x Authentikine Human IL-17A value (pg/mL)

### 9.8 Specificity

This assay recognizes natural and recombinant human IL-17A.

The following factors prepared at 50 ng/mL were assayed and exhibited no cross-reactivity or interference.

| Recombinant human: | Recombinant mouse: |
|--------------------|--------------------|
| IFN-γ              | IL-17              |
| IL-17B             |                    |
| IL-17D             |                    |
| IL-17F             |                    |
| IL-10              |                    |
| IL-12              |                    |
| IL-16              |                    |
|                    |                    |

#### 10. References

- 1. T. Mabuchi. et al. (2012). J Dermatol Sci. 65: 4-11.
- 2. X. Song. et al. (2013). Cytokine. 62: 175-182.
- 3. E. Fitch. et al. (2007). Curr Rheumatol Rep. 9: 461-467.
- 4. provided by RefSeq, Jul 2008.